ACIU · XBRL financial data

AC Immune financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ACIU's year ends in late December)

In thousands of CHF	Q4 FY17Dec 31, 2017	Q4 FY18Dec 31, 2018	Q4 FY19Dec 31, 2019	Q4 FY20Dec 31, 2020	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q4 FY25Dec 31, 2025
Revenue	16,422	1,403	year only	year only	year only	year only	year only	year only	year only
Research and development	10,176	12,129	year only	year only	year only	year only	year only	year only	year only
Operating profit (loss)	3,188	(14,487)	year only	year only	year only	year only	year only	year only	year only
Profit (loss)	4,164	(14,678)	year only	year only	year only	year only	year only	year only	year only
Earnings per share, basic CHF per share	0.07	—	—	—	—	—	—	—	—
Earnings per share, diluted CHF per share	0.07	—	—	—	—	—	—	—	—

Fiscal quarters (ACIU's year ends in late December)

In thousands of CHF	Q4 FY17Dec 31, 2017	Q4 FY18Dec 31, 2018	Q4 FY19Dec 31, 2019	Q4 FY20Dec 31, 2020	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q4 FY25Dec 31, 2025
Common shares outstanding (cover page) thousands of shares	57,355	67,562	71,859	71,937	83,479	83,620	99,198	100,410	101,742
Cash and cash equivalents	124,377	156,462	193,587	160,893	82,216	31,586	78,494	36,275	26,795
Total current assets	129,534	192,928	292,774	231,767	202,634	128,094	125,153	171,994	96,722
Total assets	132,013	196,556	299,250	238,740	261,443	185,938	182,814	230,913	154,251
Total current liabilities	9,754	13,082	17,510	14,018	20,026	11,481	13,576	100,838	94,693
Total liabilities	15,174	18,933	26,808	23,262	29,464	16,947	22,171	118,643	109,367
Total equity	116,839	177,623	272,442	215,478	231,979	168,991	160,643	112,270	44,884
Total equity and liabilities	132,013	196,556	299,250	238,740	261,443	185,938	182,814	230,913	154,251

Fiscal quarters (ACIU's year ends in late December)

In thousands of CHF	Q4 FY17Dec 31, 2017	Q4 FY18Dec 31, 2018	Q4 FY19Dec 31, 2019	Q4 FY20Dec 31, 2020	Q4 FY21Dec 31, 2021	Q4 FY22Dec 31, 2022	Q4 FY23Dec 31, 2023	Q4 FY24Dec 31, 2024	Q4 FY25Dec 31, 2025
Net cash from operating activities	year only	year only	year only	year only	year only	year only	year only	year only	year only
Net cash from investing activities	year only	year only	year only	year only	year only	year only	year only	year only	year only
Net cash from financing activities	year only	year only	year only	year only	year only	year only	year only	year only	year only

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
AC Immune	26,795	year only	year only	101.7M	—	Q4 FY25 20-FDec 31, 2025
America Great Health	29	26	1.7*	21.2B	—	Q3 FY26 10-QMar 31, 2026
AbbVie	10,774,000	17,404,000	7,606,000*	1.8B	—	Q3 FY26 10-QSep 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Abbott Laboratories	4,052,000	13,013,000	1,737,000*	1.7B	—	Q3 FY26 10-QSep 30, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	32	not reported	(244)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	322,365	342,291	11,503*	172.8M	—	Q3 FY26 10-QSep 30, 2026
Aclaris Therapeutics	20,394	1,481	(24,080)*	158.6M	5.5 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 4:48 AM ET. The filing on SEC.gov is the record.